Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03231644 · ClinicalTrials.gov registry record
Fibrous Dysplasia, McCune-Albright Syndrome Patient Registry
A clinical trial of McCune Albright Syndrome and Fibrous Dysplasia, sponsored by Tovah Burstein.
- Recruiting
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT03231644: Recruiting study of McCune Albright Syndrome and Fibrous Dysplasia, sponsored by Tovah Burstein.
NCT03231644 is a study of McCune Albright Syndrome and Fibrous Dysplasia that is actively recruiting participants, run by Tovah Burstein. The registered enrollment target is 600 participants, above the 177-participant average among 3 other McCune Albright Syndrome trials with a reported enrollment target (239% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03231644, a study of McCune Albright Syndrome and Fibrous Dysplasia, is actively recruiting participants, sponsored by Tovah Burstein.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
The FD/MAS Patient Registry is an IRB-approved research study that that invites the patients and families to help answer some of the biggest questions about FD/MAS by completing questionnaires about their lives with FD or MAS. Have you enrolled in the FD/MAS Patient Registry yet? Are you up-to-date on your surveys? Take a trip to www.fdmasregistry.org today to learn more about the project, enroll, complete your surveys, or make sure you aren't due to provide more info! The FD/MAS Patient Registry: Your story powers research.
Primary Outcome
FACIT-Treatment Satisfaction scale
Conditions Studied
Study Locations (1)
Maryland
- Tovah Burstein - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2016-10-31 |
| Est. Completion | 2028-10 |
What NCT03231644 shows while recruiting
NCT03231644 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 177-participant average among 3 other McCune Albright Syndrome trials with a reported enrollment target (239% higher).
The record links to 3 conditions, with McCune Albright Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT03231644 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT03231644 about?
NCT03231644 is a clinical study titled "Fibrous Dysplasia, McCune-Albright Syndrome Patient Registry". The FD/MAS Patient Registry is an IRB-approved research study that that invites the patients and families to help answer some of the biggest questions about FD/MAS by completing questionnaires about their lives with FD or MAS. Have you enrolled in the FD/MAS Patient Registry yet? Are you up-to-date...
What is the current status of trial NCT03231644?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2016-10-31. Estimated completion is 2028-10.
What conditions does trial NCT03231644 study?
This clinical trial studies the following conditions: McCune Albright Syndrome, Fibrous Dysplasia, Mazabraud Syndrome.
Who is sponsoring clinical trial NCT03231644?
This trial is sponsored by Tovah Burstein, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03231644 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for McCune Albright Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI